The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
I do think it's interesting and important to point out that things like agmatine, things like SAMe have been shown under certain circumstances to be beneficial for pain and they are outside the realm of prescription drugs.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
Look, at the end of the day these are compounds that affect cellular processes. And the more that we understand how they affect those cellar processes as we now do for things like acetylcarnitine, I think the more trust that we can put into them, or the more to which we might want to avoid them because of some of the side effects or contra-indications that those compounds could have.
Both of those have been shown to have some impact categorized on examine as notable impact on various forms of pain, due to osteoarthritis, or due to injury of various kinds of indifferent subject population, men, women, people of different ages, et cetera.